___

Maeder ML, Gersbach CA. Genome-editing Technologies for Gene and Cell Therapy. Mol Ther. 2016; 24(3): 430-46.

Rouet P, Smih F, Jasin M. Expression of a site-specific endonu- clease stimulates homologous recombination in mammalian cells. Proc Natl Acad Sci U S A. 1994; 91(13): 6064-8.

Belfort M, Roberts RJ. Homing endonucleases: keeping the house in order. Nucleic Acids Res. 1997; 25(17): 3379-88.

Bibikova M, Golic M, Golic KG, et al. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics. 2002; 161(3): 1169-75.

Doyon Y, Vo TD, Mendel MC, et al. Enhancing zinc-finger-nu- clease activity with improved obligate heterodimeric archi- tectures. Nat Methods. 2011; 8(1): 74-9.

Boch J, Scholze H, Schornack S, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009; 326(5959): 1509-12.

Boissel S, Jarjour J, Astrakhan A, et al. megaTALs: a rare-cleav- ing nuclease architecture for therapeutic genome engineer- ing. Nucleic Acids Res. 2014; 42(4): 2591-601.

Jore MM, Lundgren M, van Duijn E, et al. Structural basis for CRISPR RNA-guided DNA recognition by Cascade. Nat Struct Mol Biol. 2011; 18(5): 529-36. [9] Jinek M, Chylinski K, Fonfara I, et al. Science. A programma- ble dual-RNA-guided DNA endonuclease in adaptive bacteri- al immunity. 2012; 337(6096): 816-21.

Zetsche B, Gootenberg JS, Abudayyeh OO, et al. Cpf1 is a sin- gle RNA-guided endonuclease of a class 2 CRISPR-Cas sys- tem. Cell. 2015 Oct 22;163(3):759-71.

Moreno-Mateos MA, Fernandez JP, Rouet R, et al. CRISPR- Cpf1 mediates efficient homology-directed repair and temperature-controlled genome editing. BioRxiv 2017 Jun: doi: http://dx.doi.org/10.1101/156125.

Ran FA, Cong L, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015; 520(7546): 186-91.

Kleinstiver BP, Prew MS, Tsai SQ, et al. Engineered CRISPR- Cas9 nucleases with altered PAM specificities. Nature. 2015; 523(7561): 481-5.

Takata M, Sasaki MS, Sonoda E, et al. Homologous recombi- nation and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J. 1998; 17(18): 5497-508.

Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas- based methods for genome engineering. Trends Biotechnol. 2013; 31(7): 397-405.

Canver MC, Bauer DE, Dass A, et al. Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J Biol Chem. 2014; 289(31): 21312-24.

Brunet E, Simsek D, Tomishima M, et al. Chromosomal trans- locations induced at specified loci in human stem cells. Proc Natl Acad Sci U S A. 2009; 106(26):10620-5.

Hoban MD, Bauer DE. A genome editing primer for the hema- tologist. Blood. 2016; 127(21): 2525-35.

Mao Z, Bozzella M, Seluanov A, et al. Comparison of nonho- mologous end joining and homologous recombination in human cells. DNA Repair (Amst). 2008; 7(10): 1765-71.

Chu VT, Weber T, Wefers B, et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol. 2015; 33(5): 543-8.

Monteys AM, Ebanks SA, Keiser MS, et al. CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo. Mol Ther. 2017 Jan 4;25(1):12-23.

Su S, Zou Z, Chen F, et al. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology. 2016 Nov 22;6(1): e1249558.

Reik A, Holmes MC, Zhou Y, et al. (2007). Targeted killing of glioblastoma multiforme in vivo by IL-13 zetakine redirected CTLs made glucocorticoid resistant with zinc finger nucleas- es. Blood. 2007; 110: 2597-99.

Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resis- tance in CD4+ T cells by genome editing using zinc-finger nu- cleases. Nat Biotechnol. 2008; 26: 808–816.

Holt N, Wang J, Kim K, et al. Human hematopoietic stem/pro- genitor cells modified by zinc- finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010; 28: 839–847.

NIH, US National Library of Medicine. https://clinicaltrials.gov (accessed February 2018)

Xiao A, Wang Z, Hu Y, et al. Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res. 2013; 41(14): e141.

Xiao A, Zhang B. Generation of Targeted Genomic Deletions Through CRISPR/Cas System in Zebrafish. Methods Mol Biol. 2016; 1451: 65-79.

Ousterout DG, Kabadi AM, Thakore PI, et al. Multiplex CRISPR/ Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun. 2015; 6: 6244.

Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science. 2013; 342(6155): 253-7. [31] Canver MC, Smith EC, Sher F, et al. BCL11A enhancer dis- section by Cas9-mediated in situ saturating mutagenesis. Nature. 2015; 527(7577): 192-7.

Hu W, Kaminski R, Yang F, et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infec- tion. Proc Natl Acad Sci U S A. 2014; 111(31): 11461-6.

Komor AC, Kim YB, Packer MS, et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533(7603): 420-4.

Zhang Y, Qin W, Lu X, et al. Programmable base editing of ze- brafish genome using a modified CRISPR-Cas9 system. Nat Commun. 2017; 8(1): 118.

Hoban MD, Cost GJ, Mendel MC, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progen- itor cells. Blood. 2015; 125(17): 2597-604.

Yin H, Xue W, Chen S, Bogorad RL, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and pheno- type. Nat Biotechnol. 2014; 32(6): 551-3.

Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature. 2014; 510(7504): 235-240.

Voit RA, Hendel A, Pruett-Miller SM, et al. Nuclease-mediated gene editing by homologous recombination of the human globin locus. Nucleic Acids Res. 2014; 42(2): 1365-78.

Zou J, Sweeney CL, Chou BK, et al. Oxidase-deficient neutro- phils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood. 2011; 117(21): 5561-72.

Sharma R, Anguela XM, Doyon Y, et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood. 2015; 126(15): 1777-84.

Prakash V, Moore M, Yáñez-Muñoz RJ. Current Progress in Therapeutic Gene Editing for Monogenic Diseases. Mol Ther. 2016; 24(3): 465-74.

Doudna JA, Sontheimer EJ. Methods in Enzymology. The use of CRISPR/Cas9, ZFNs, and TALENs in generating site-specif- ic genome alterations. Preface. Methods Enzymol. 2014; 546: xix-xx.

Zu Y, Tong X, Wang Z, et al. TALEN-mediated precise genome modification by homologous recombination in zebrafish. Nat Methods. 2013; 10(4): 329-31.

Yoshimi K, Kunihiro Y, Kaneko T, et al. ssODN-mediated knock- in with CRISPR-Cas for large genomic regions in zygotes. Nat Commun. 2016; 7: 10431.

Richardson CD, Ray GJ, DeWitt MA, et al. Enhancing homol- ogy-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol. 2016; 34(3): 339-44.

Kocher T, Peking P, Klausegger A, et al. Cut and Paste: Efficient Homology-Directed Repair of a Dominant Negative KRT14 Mutation via CRISPR/Cas9 Nickases. Mol Ther. 2017; 25(11): 2585-2598.

Suzuki K, Tsunekawa Y, Hernandez-Benitez R, et al. In vivo ge- nome editing via CRISPR/Cas9 mediated homology-indepen- dent targeted integration. Nature. 2016; 540(7631): 144-149.

Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in au- tologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10): 901-10. [49] Editas Medicine. https://www.editasmedicine.com (accessed February 2018)

Sangamo Therapeutics. https://www.sangamo.com/prod- uct-pipeline (accessed February 2018)

Sternberg SH, Redding S, Jinek M, et al. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature. 2014;507(7490): 62-7.

Müller M, Lee CM, Gasiunas G, et al. Streptococcus thermo- philus CRISPR-Cas9 Systems Enable Specific Editing of the Human Genome. Mol Ther. 2016; 24(3): 636-44.

Lee CM, Cradick TJ, Bao G. The Neisseria meningitidis CRISPR- Cas9 System Enables Specific Genome Editing in Mammalian Cells. Mol Ther. 2016; 24(3): 645-54.

Zhang JH, Adikaram P, Pandey M, et al. Optimization of genome editing through CRISPR-Cas9 engineering. Bioengineered. 2016; 7(3): 166-74.

Miller JC, Holmes MC, Wang J, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol. 2007; 25(7): 778-85.

Sather BD, Romano Ibarra GS, Sommer K, et al. Efficient mod- ification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med. 2015; 7(307): 307ra156.

Fu Y, Foden JA, Khayter C, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013 Sep;31(9):822-6.

Bolukbasi MF, Gupta A, Oikemus S, et al. DNA-binding- domain fusions enhance the targeting range and precision of Cas9. Nat Methods. 2015; 12(12): 1150-6.

Slaymaker IM, Gao L, Zetsche B, et al. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016; 351(6268): 84-8.

Petris G, Casini A, Montagna C, et al. Hit and go CAS9 de- livered through a lentiviral based self-limiting circuit. Nat Commun. 2017; 8: 15334.

Hendel A, Bak RO, Clark JT, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human prima- ry cells. Nat Biotechnol. 2015; 33(9): 985-989.

Lux CT, Scharenberg AM. Therapeutic Gene Editing Safety and Specificity. Hematol Oncol Clin North Am. 2017; 31(5): 787-795.

Martin F, Sánchez-Hernández S, Gutiérrez-Guerrero A, et al. Biased and Unbiased Methods for the Detection of Off-Target Cleavage by CRISPR/Cas9: An Overview. Int J Mol Sci. 2016; 17(9): E1507.

Gabriel R, Lombardo A, Arens A, et al. An unbiased ge-nome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol. 2011;29(9): 816-23.

Mali P, Aach J, Stranges PB, et al. CAS9 transcriptional acti- vators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013; 31(9): 833-8.

Tsai SQ, Zheng Z, Nguyen NT, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015; 33(2): 187-197.

Hu J, Meyers RM, Dong J, et al. Detecting DNA double-strand- ed breaks in mammalian genomes by linear amplifica- tion-mediated high-throughput genome-wide translocation sequencing. Nat Protoc. 2016; 11(5): 853-71.

Park J, Childs L, Kim D, et al. Digenome-seq web tool for pro- filing CRISPR specificity. Nat Methods. 2017; 14(6): 548-549.

Veres A, Gosis BS, Ding Q, et al. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted hu- man stem cell clones detected by whole-genome sequenc- ing. Cell Stem Cell. 2014; 15(1): 27-30.

Mout R, Ray M, Lee YW, et al. In Vivo Delivery of CRISPR/ Cas9 for Therapeutic Gene Editing: Progress and Challenges. Bioconjug Chem. 2017; 28(4): 880-884.

Beane JD, Lee G, Zheng Z, et al. Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. Mol Ther. 2015; 23(8): 1380-1390.

Wang J, Exline CM, DeClercq JJ, et al. Homology-driven ge- nome editing in hematopoietic stem and progenitor cells us- ing ZFN mRNA and AAV6 donors. Nat Biotechnol. 2015; 33(12): 1256-1263.

Kim S, Kim D, Cho SW, et al. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ri- bonucleoproteins. Genome Res. 2014; 24(6): 1012-9.

Schumann K, Lin S, Boyer E, et al. Generation of knock-in pri- mary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A. 2015; 112(33): 10437-42.

Holkers M, Maggio I, Liu J, et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res. 2013; 41(5): e63.

Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol. 2007; 25(11): 1298-306.

Ding Q, Strong A, Patel KM, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014; 115(5): 488-92.

Asokan A, Schaffer DV, Samulski RJ. The AAV vector tool- kit: poised at the clinical crossroads. Mol Ther. 2012; 20(4): 699-708.

Anguela XM, Sharma R, Doyon Y, et al. Robust ZFN-mediated genome editing in adult hemophilic mice. Blood. 2013; 122(19): 3283-7.

Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature. 2011; 475(7355): 217-21.

Long C, Amoasii L, Mireault AA, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016; 351(6271): 400-3.

Zhen S, Hua L, Liu YH, et al. Harnessing the clustered regu- larly interspaced short palindromic repeat (CRISPR)/CRISPR- associated Cas9 system to disrupt the hepatitis B virus. Gene Ther. 2015; 22(5): 404-12.

Lorden ER, Levinson HM, Leong KW. Integration of drug, protein, and gene delivery systems with regenerative med- icine. Drug Deliv Transl Res. 2015; 5(2): 168-86.

Sun W, Ji W, Hall JM, et al. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew Chem Int Ed Engl. 2015; 54(41): 12029-33.

Lee K, Conboy M, Park HM, et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng, 2017; 1: 889-901.

Gaskell G, Bard I, Allansdottir A, et al. Public views on gene editing and its uses. Nat Biotechnol. 2017; 35(11): 1021-1023.

Kohn DB, Porteus MH, Scharenberg AM. Ethical and regulatory aspects of genome editing. Blood. 2016; 127(21): 2553-60.

Hyun I, Osborn C. Query the merits of embryo editing for reproductive research now. Nat Biotechnol. 2017; 35(11): 1023-1025.

Fogarty NME, McCarthy A, Snijders KE, et al. Genome edit- ing reveals a role for OCT4 in human embryogenesis. Nature. 2017; 550(7674): 67-73.

Cho S. W, Kim S, Kim J. M. & Kim J. S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 2013; 31, 230–232.

Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013; 153, 910–918.

Guo, X. & Li, X. J. Targeted genome editing in primate embry- os. Cell Res. 2015; 25: 767–768.

Ma H, Marti-Gutierrez N, Park SW, et al. Correction of a pathogenic gene mutation in human embryos. Nature. 2017; 548(7668): 413-419.

Cwik B. Designing Ethical Trials of Germline Gene Editing. N Engl J Med. 2017; 377(20): 1911-1913.

Cetin N, Balcı-Hayta B, Gundesli H, et al. A novel desmin mutation leading to autosomal recessive limb-girdle muscular dystrophy: distinct histopathological outcomes compared with desminopathies. J Med Genet. 2013; 50(7): 437-43.